Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2005.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

n 1449/PTO

Sheet

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/069,626	_			
Filing Date	July 25, 2002				
First Named Inventor	Cynthia GREEN	_			
Art Unit	1644	_			
Examiner Name	Ilia I. Ouspenski	_			
Attorney Docket Number	2159.0960004/EKS/PAC	_			

U.S. PATENT DOCUMENTS								
Initials' No.1	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines,			
	Number-Kind Code <sup>2 (If Known)</sup>	MIM-DD-1111	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear				
					<u>.</u>			
			<u> </u>					
			<del> </del>					
			<del> </del>					
			<del> </del>		<del>                                     </del>			
				· · · · · · · · · · · · · · · · · · ·				
			<del>                                     </del>		<u> </u>			
					<del>                                     </del>			
			<u> </u>					

FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.			Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Country Code <sup>3</sup> Number <sup>6</sup> Kind Code <sup>3</sup> (if known)			Relevant Passages or Relevant Figures Appear	Т		
IO	FP1	WO 99/46281 A2	09/16/1999	Genentech, Inc.		Г		
IO	FP2	WO 00/68266 A1	11/16/2000	Eli Lilly and Company				
						╀		
						H		
						┞		
						┝		

Examiner	/Ilia Ouspenski/	Date	10/05/2006
Signature		Considered	20,03,2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 'Applicant's unique citation designation number (optional), 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 'For

of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Confide for form 1449/PTO Complete if Known 10/069,626 Application Number INFORMATION DISCLOSURE Filing Date July 25, 2002 First Named Inventor Cynthia GREEN STATEMENT BY APPLICANT Art Unit 1644 (Use as many sheets as necessary) **Examiner Name** Ilia I. Ouspenski Attorney Docket Number 2159.0960004/EKS/PAC Sheet of 2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	Τ²
10 	NPLI	Abbas, A K. and Sharpe, A.H., "T-cell stimulation: an abundance of B7s," Nat. Med. 5:1345-1346, Nature America, Inc. (December 1999)	
	NPL2	Branch, A.D., "A good antisense molecule is hard to find," <i>Trends Biochem. Sci.</i> 23:45-50, Elsevier Science Ltd. (February 1998)	
	NPL3	Chapoval, A.I., et al., "B7-H3: A costimulatory molecule for T cell activation and IFN-γ production," Nat. Immunol. 2:269-274, Nature America, Inc. (March 2001)	
	NPL4	Dong, H., et al., "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," Nat. Med. 5:1365-1369, Nature America, Inc. (December 1999)	
	NPL5	Freeman, G.J., et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," J. Exp. Med. 174:625-631, The Rockefeller University Press (1991)	
	NPL6	Greenfield, E.A., et al., "CD28/B7 Costimulation: A Review," Crit. Rev. Immunol. 18:389-418, Begell House, Inc. (1998)	
	NPL7	Janeway, C.A., et al., eds., "Chapter 7. The Adaptive Immune Response," in: Immunobiology - The Immune System in Health and Disease," 3 <sup>rd</sup> Ed., Garland Publishing Inc., New York, NY, pp. 7:1-7:44 (1997)	
	NPL8	Ling, V., et al., "Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor," J. Immunol. 164:1653-1657, The American Association of Immunologists (February 2000)	
$\sqrt{}$	NPL9	Linsley, P.S., et al., "Extending the B7 (CD80) gene family," Prot. Sci. 3:1341-1343, Cambridge University Press (1994)	
10	NPL10	Mountain, A., "Gene therapy: the first decade," Trends Biotechnol. 18:119-128, Elsevier Science Ltd. (March 2000)	
	1 ,	Ilia Ouspenski/ 10/05/2006	L

Examiner		Date	
Signature	•	Considered	
-			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number.

Substitute for	Substitute for the PTO			Complete if Known		
		Application Number	10/069,626			
INFORMATION DISCLOSURE				Filing Date	July 25, 2002	
	STATEMENT BY APPLICANT		First Named Inventor	Cynthia GREEN		
	(Use as many			Art Unit	1644	
	•			Examiner Name	Ilia I. Ouspenski	
Sheet	2	of	2	Attorney Docket Number	2159.0960004/EKS/PAC	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T²
IO NPL11		Nishimura, Y., et al., "Molecular cloning of the cDNAs encoding the feline B-lymphocyte activation antigen B7-1 (CD90) and B7-2 (CD86) homologues which interact with human CTLA4-Ig," Eur. J. Immunogen. 27:427-430, Blackwell Science Ltd. (December 2000)	
	NPL12	Selvakumar, A., et al., "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," <i>Immunogen</i> . 36:175-181, Springer International (1992)	
	NPL13	Skolnick, J. and Fetrow, J.S., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39, Elsevier Science Ltd. (January 2000)	
	NPL14	Swallow, M.M., et al., "B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFa," <i>Immunity 11</i> :423-432, Cell Press (October 1999)	
	NPL15	Thompson, C.B., "Distinct Roles for the Costimulatory Ligands B7-1 and B7-2 in T Helper Cell Differentiation?," Cell 81:979-982, Cell Press (1995)	
	NPL16	Voet, S. and Voet, J.G., "3. Chemical Evolution," in: Biochemistry, John Wiley & Sons, New York, NY, pp. 126-230 (1990)	
	NPL17	Zhang, D. and Johnson, R.P., "Molecular Cloning and Comparative Analysis of the Rhesus Macaque Costimulatory Molecules CD80 (B7-1) and CD86 (B7-2)," Cellul. Immunol. 177:9-17, Academic Press (1997)	
10			

506914v1

/Ilia Ouspenski/

10/05/2006

Examiner	Date	
Signature	Considered	•

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.